Literature DB >> 3874920

Thalidomide--effect on T cell subsets as a possible mechanism of action.

B Moncada, M L Baranda, R González-Amaro, R Urbina, C E Loredo.   

Abstract

Thalidomide is the drug of choice in the erythema nodosum leprosum (ENL) type of lepra reaction. Lately it has been used successfully in other diseases, such as discoid lupus erythematosus, actinic prurigo, Behcet's disease, etc. However, its mechanism of action remains unknown. In patients for whom thalidomide provided relief in their disorder, the proportions of T lymphocytes and their subsets in peripheral blood were assessed by means of monoclonal antibodies. Three lepromatous leprosy patients with ENL had their T helper populations significantly increased after thalidomide therapy. A 14-year-old girl with Behcet's syndrome showed a consistent decrease in Ia+ cells throughout her three-month course of thalidomide therapy. The same findings were observed in two patients with the actinic prurigo type of polymorphous light eruption. From these results, we conclude that thalidomide may act as an immunomodulating agent on T cell subsets.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874920

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  13 in total

1.  Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.

Authors:  M Youle; J Clarbour; C Farthing; M Connolly; D Hawkins; R Staughton; B Gazzard
Journal:  BMJ       Date:  1989-02-18

2.  Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice.

Authors:  H Kröger; R Miesel; A Dietrich; M Ohde; E Rajnavölgyi; H Ockenfels
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

Review 3.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

4.  Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.

Authors:  Michael Medinger; Natalie Fischer; Alexandar Tzankov
Journal:  J Oncol       Date:  2010-05-24       Impact factor: 4.375

5.  Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.

Authors:  R Neubert; A C Nogueira; D Neubert
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

6.  Suppressor response in lepromatous leprosy patients: role of Leu 2a cells.

Authors:  M del Carmen Sasiain; S de la Barrera; B Ruibal-Ares; J E Cardama; J C Gatti; M M de Bracco
Journal:  Immunology       Date:  1987-01       Impact factor: 7.397

7.  Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.

Authors:  Anna Dmoszynska; Monika Podhorecka; Piotr Klimek; Norbert Grzasko
Journal:  Eur J Clin Pharmacol       Date:  2006-03-08       Impact factor: 2.953

8.  Clinical trials with anti-angiogenic agents in hematological malignancies.

Authors:  Michael Medinger; Klaus Mross
Journal:  J Angiogenes Res       Date:  2010-06-22

Review 9.  Mechanism of action of lenalidomide in hematological malignancies.

Authors:  Venumadhav Kotla; Swati Goel; Sangeeta Nischal; Christoph Heuck; Kumar Vivek; Bhaskar Das; Amit Verma
Journal:  J Hematol Oncol       Date:  2009-08-12       Impact factor: 17.388

10.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Authors:  E P Sampaio; E N Sarno; R Galilly; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.